341 related articles for article (PubMed ID: 26966785)
1. Advances in the pharmacological treatment of Graves' orbitopathy.
Ruchała M; Sawicka-Gutaj N
Expert Rev Clin Pharmacol; 2016 Jul; 9(7):981-9. PubMed ID: 26966785
[TBL] [Abstract][Full Text] [Related]
2. Optimal management of Graves orbitopathy: a multidisciplinary approach.
Soeters MR; van Zeijl CJ; Boelen A; Kloos R; Saeed P; Vriesendorp TM; Mourits MP
Neth J Med; 2011; 69(7):302-8. PubMed ID: 21934174
[TBL] [Abstract][Full Text] [Related]
3. Mechanistic Pathways of Selenium in the Treatment of Graves' Disease and Graves' Orbitopathy.
Marinò M; Dottore GR; Leo M; Marcocci C
Horm Metab Res; 2018 Dec; 50(12):887-893. PubMed ID: 30096720
[TBL] [Abstract][Full Text] [Related]
4. Novel treatment modalities for Graves' orbitopathy.
Bartalena L; Lai A; Sassi L; Lombardi V; Dalle Mule I; Gandolfo M; Liparulo L; Azzolini C; Piantanida E; Tanda ML
Pediatr Endocrinol Rev; 2010 Mar; 7 Suppl 2():210-6. PubMed ID: 20467365
[TBL] [Abstract][Full Text] [Related]
5. Current and Emerging Treatment Strategies for Graves' Orbitopathy.
Genere N; Stan MN
Drugs; 2019 Feb; 79(2):109-124. PubMed ID: 30659423
[TBL] [Abstract][Full Text] [Related]
6. Challenges and perspectives of selenium supplementation in Graves' disease and orbitopathy.
Bednarczuk T; Schomburg L
Hormones (Athens); 2020 Mar; 19(1):31-39. PubMed ID: 31721133
[TBL] [Abstract][Full Text] [Related]
7. Current concepts regarding Graves' orbitopathy.
Bartalena L; Tanda ML
J Intern Med; 2022 Nov; 292(5):692-716. PubMed ID: 35604323
[TBL] [Abstract][Full Text] [Related]
8. Sustained control of Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves' orbitopathy.
Laurberg P; Berman DC; Andersen S; Bülow Pedersen I
Thyroid; 2011 Sep; 21(9):951-6. PubMed ID: 21834677
[TBL] [Abstract][Full Text] [Related]
9. [Graves' ophthalmopathy from the internist's perspective].
Laubner K; Weber WA; Seufert J
Ophthalmologe; 2011 May; 108(5):410-6. PubMed ID: 21590351
[TBL] [Abstract][Full Text] [Related]
10. [Graves' orbitopathy].
Balázs C
Orv Hetil; 2006 Jun; 147(22):1011-7. PubMed ID: 16913090
[TBL] [Abstract][Full Text] [Related]
11. Optimization of the treatment of moderate to severe and active thyroid orbitopathy considering the recommendations of the European Group on Graves' Orbitopathy (EUGOGO) [Optymalizacja leczenia umiarkowanej do ciężkiej i aktywnej orbitopatii tarczycowej z uwzględnieniem zaleceń European Group on Graves' Orbitopathy (EUGOGO)].
Nowak M; Marek B; Kos-Kudła B; Siemińska L; Londzin-Olesik M; Głogowska-Szeląg J; Nowak W; Kajdaniuk D
Endokrynol Pol; 2022; 73(4):756-777. PubMed ID: 36059167
[TBL] [Abstract][Full Text] [Related]
12. Selenium in the Treatment of Graves' Hyperthyroidism and Eye Disease.
Lanzolla G; Marinò M; Marcocci C
Front Endocrinol (Lausanne); 2020; 11():608428. PubMed ID: 33574798
[TBL] [Abstract][Full Text] [Related]
13. Survey of common practices among oculofacial surgeons in the Asia-Pacific region: Graves' orbitopathy.
Sundar G; Chiam N; Lun K; Koh V
Orbit; 2014 Oct; 33(5):319-25. PubMed ID: 25121573
[TBL] [Abstract][Full Text] [Related]
14. Combined thyroid eye clinic: the importance of a multidisciplinary health care in patients with Graves' orbitopathy.
Wiersinga WM
Pediatr Endocrinol Rev; 2010 Mar; 7 Suppl 2():250-3. PubMed ID: 20467372
[TBL] [Abstract][Full Text] [Related]
15. Treatment of mild, moderate-to-severe and very severe Graves' orbitopathy.
Marcocci C; Marinò M
Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):325-37. PubMed ID: 22632369
[TBL] [Abstract][Full Text] [Related]
16. Childhood Graves' ophthalmopathy: results of a European questionnaire study.
Krassas GE; Segni M; Wiersinga WM
Eur J Endocrinol; 2005 Oct; 153(4):515-21. PubMed ID: 16189172
[TBL] [Abstract][Full Text] [Related]
17. Graves' orbitopathy: a multidisciplinary approach.
Limone PP; Mellano M; Ruo Redda MG; Macera A; Ferrero V; Sellari Franceschini S; Deandrea M
Q J Nucl Med Mol Imaging; 2021 Jun; 65(2):157-171. PubMed ID: 33634673
[TBL] [Abstract][Full Text] [Related]
18. Effects of treatment modalities for Graves' hyperthyroidism on Graves' orbitopathy: a 2015 Italian Society of Endocrinology Consensus Statement.
Bartalena L; Macchia PE; Marcocci C; Salvi M; Vermiglio F
J Endocrinol Invest; 2015 Apr; 38(4):481-7. PubMed ID: 25722226
[No Abstract] [Full Text] [Related]
19. Current and Future Treatments for Graves' Disease and Graves' Ophthalmopathy.
Kotwal A; Stan M
Horm Metab Res; 2018 Dec; 50(12):871-886. PubMed ID: 30286486
[TBL] [Abstract][Full Text] [Related]
20. Thyroid-associated orbitopathy: who and how to treat.
Dickinson J; Perros P
Endocrinol Metab Clin North Am; 2009 Jun; 38(2):373-88, ix. PubMed ID: 19328417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
